• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Solid Biosciences (SLDB)

Common Shares
Sell: $3.06|Buy: $3.09|Change: 0.18 (-5.57%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Address

141 Portland Street
Fifth Floor
Cambridge
MA
USA
02139

Telephone

+1 617 3374680

Website

https://www.solidbio.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Solid Biosciences Inc Fourth Quarter Earnings Results for 20252026-03-06T00:00:00
Solid Biosciences Inc Annual Report for 20252026-03-06T00:00:00
Solid Biosciences Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
Solid Biosciences Inc Second Quarter Earnings Results for 20252025-08-13T00:00:00
Solid Biosciences Inc Annual General Meeting for 20252025-06-11T08:00:00
Solid Biosciences Inc First Quarter Earnings Results for 20252025-05-15T00:00:00

Previous key dates

NameKey Date
Barclays 27th Annual Global Healthcare Conference2025-03-13T09:30:00
Leerink Global Healthcare Conference2025-03-12T09:20:00
Solid Biosciences Inc Fourth Quarter Earnings Results for 20242025-03-06T00:00:00
Solid Biosciences Inc Annual Report for 20242025-03-06T00:00:00
SGT-003 INSPIRE DUCHENNE Data Update Conference Call2025-02-18T08:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-15T15:45:00
Solid Biosciences Piper Sandler 36th Annual Healthcare Conference 20242024-12-05T09:30:00
Solid Biosciences Citi - 2024 Global Healthcare Conference2024-12-04T13:00:00
Jefferies London Healthcare Conference2024-11-20T13:30:00
Solid Biosciences Inc Third Quarter Earnings Results for 20242024-11-06T00:00:00
Chardan’s 8th Annual Genetic Medicines Conference2024-09-30T11:00:00
2024 Cantor Global Healthcare Conference2024-09-18T10:20:00
H.C. Wainwright 26th Annual Global investment Conference2024-09-10T09:30:00
Solid Biosciences Inc Second Quarter Earnings Results for 20242024-08-13T00:00:00
Solid Biosciences Inc Annual General Meeting for 20242024-06-11T08:00:00
Solid Biosciences Inc First Quarter Earnings Results for 20242024-05-15T00:00:00
Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium2024-04-02T08:15:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.